Literature DB >> 11316590

P53 and PML: new partners in tumor suppression.

V Gottifredi, C Prives.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11316590     DOI： 10.1016/s0962-8924(01)01983-3

Source DB:  PubMed          Journal:  Trends Cell Biol        ISSN： 0962-8924            Impact factor:   20.808


× No keyword cloud information.
  12 in total

1.  Targeting protein inactivation through an oligomerization chain reaction.

Authors:  Francesco Contegno; Mario Cioce; Pier Giuseppe Pelicci; Saverio Minucci
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-12       Impact factor: 11.205

2.  Impairment of p53 acetylation, stability and function by an oncogenic transcription factor.

Authors:  Alessandra Insinga; Silvia Monestiroli; Simona Ronzoni; Roberta Carbone; Mark Pearson; Giancarlo Pruneri; Giuseppe Viale; Ettore Appella; PierGiuseppe Pelicci; Saverio Minucci
Journal:  EMBO J       Date:  2004-02-19       Impact factor: 11.598

3.  Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner.

Authors:  Sue Haupt; Catherine Mitchell; Vincent Corneille; Jake Shortt; Stephen Fox; Pier Paolo Pandolfi; Mireia Castillo-Martin; Dennis M Bonal; Carlos Cordon-Cardo; Guillermina Lozano; Ygal Haupt
Journal:  Cell Cycle       Date:  2013-05-08       Impact factor: 4.534

Review 4.  PML nuclear bodies: assembly and oxidative stress-sensitive sumoylation.

Authors:  Umut Sahin; Hugues de Thé; Valérie Lallemand-Breitenbach
Journal:  Nucleus       Date:  2014       Impact factor: 4.197

5.  Nuclear localization but not PML protein is required for incorporation of the papillomavirus minor capsid protein L2 into virus-like particles.

Authors:  Katrin A Becker; Luise Florin; Cornelia Sapp; Gerd G Maul; Martin Sapp
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

6.  Cell cycle arrest by Kaposi's sarcoma-associated herpesvirus replication-associated protein is mediated at both the transcriptional and posttranslational levels by binding to CCAAT/enhancer-binding protein alpha and p21(CIP-1).

Authors:  Frederick Y Wu; Shizhen Emily Wang; Qi-Qun Tang; Masahiro Fujimuro; Chuang-Jiun Chiou; Qizhi Zheng; Honglin Chen; S Diane Hayward; M Daniel Lane; Gary S Hayward
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

7.  Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomes.

Authors:  Mark N Prichard; Elizabeth Sztul; Shannon L Daily; Amie L Perry; Samuel L Frederick; Rachel B Gill; Caroll B Hartline; Daniel N Streblow; Susan M Varnum; Richard D Smith; Earl R Kern
Journal:  J Virol       Date:  2008-03-05       Impact factor: 5.103

Review 8.  Progressive multifocal leukoencephalopathy and promyelocytic leukemia nuclear bodies: a review of clinical, neuropathological, and virological aspects of JC virus-induced demyelinating disease.

Authors:  Yukiko Shishido-Hara
Journal:  Acta Neuropathol       Date:  2010-05-13       Impact factor: 17.088

Review 9.  The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies.

Authors:  Hugues de Thé; Morgane Le Bras; Valérie Lallemand-Breitenbach
Journal:  J Cell Biol       Date:  2012-07-09       Impact factor: 10.539

10.  Mad1 destabilizes p53 by preventing PML from sequestering MDM2.

Authors:  Jun Wan; Samuel Block; Christina M Scribano; Rebecca Thiry; Karla Esbona; Anjon Audhya; Beth A Weaver
Journal:  Nat Commun       Date:  2019-04-04       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.